David Jones

13.1k total citations · 1 hit paper
169 papers, 7.3k citations indexed

About

David Jones is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, David Jones has authored 169 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Hepatology, 78 papers in Epidemiology and 50 papers in Surgery. Recurrent topics in David Jones's work include Liver Diseases and Immunity (106 papers), Liver Disease Diagnosis and Treatment (69 papers) and Pediatric Hepatobiliary Diseases and Treatments (36 papers). David Jones is often cited by papers focused on Liver Diseases and Immunity (106 papers), Liver Disease Diagnosis and Treatment (69 papers) and Pediatric Hepatobiliary Diseases and Treatments (36 papers). David Jones collaborates with scholars based in United Kingdom, United States and Canada. David Jones's co-authors include Gideon M. Hirschfield, Ulrich Beuers, Pietro Invernizzi, Julia L. Newton, Oliver James, Margaret F. Bassendine, Christoph Schramm, Marco Marzioni, Christophe Corpechot and Alan G. Scarlett and has published in prestigious journals such as Nature, The Lancet and Nucleic Acids Research.

In The Last Decade

David Jones

165 papers receiving 7.1k citations

Hit Papers

EASL Clinical Practice Guidelines: The diagnosis and mana... 2017 2026 2020 2023 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
    2017 886 citations Gideon M. Hirschfield, Pietro Invernizzi et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Jones United Kingdom 44 4.2k 3.7k 2.3k 875 568 169 7.3k
Rudolf Stauber Austria 47 3.5k 0.8× 3.4k 0.9× 932 0.4× 460 0.5× 351 0.6× 224 6.7k
Zhiping Li China 31 621 0.1× 1.5k 0.4× 670 0.3× 377 0.4× 259 0.5× 226 4.8k
W.H.J. Summerskill United States 50 3.3k 0.8× 3.6k 1.0× 2.9k 1.3× 991 1.1× 746 1.3× 151 8.9k
Xin Gao China 47 509 0.1× 2.4k 0.6× 1.3k 0.6× 664 0.8× 383 0.7× 466 9.1k
R. P. H. Thompson United Kingdom 42 218 0.1× 719 0.2× 812 0.4× 316 0.4× 347 0.6× 163 5.9k
Andrea Fabbri Italy 37 781 0.2× 1.2k 0.3× 705 0.3× 109 0.1× 169 0.3× 188 4.3k
Keh‐Sung Tsai Taiwan 49 737 0.2× 1.4k 0.4× 1.3k 0.6× 841 1.0× 228 0.4× 164 6.5k
Liang Du China 30 620 0.1× 516 0.1× 681 0.3× 507 0.6× 430 0.8× 170 3.5k
Wladimiro Jiménez Spain 63 10.8k 2.6× 8.5k 2.3× 5.8k 2.6× 451 0.5× 2.0k 3.5× 307 15.9k
Srinivasan Dasarathy United States 62 7.0k 1.7× 10.3k 2.8× 2.7k 1.2× 830 0.9× 403 0.7× 237 16.6k

Countries citing papers authored by David Jones

Since Specialization
Citations

This map shows the geographic impact of David Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Jones more than expected).

Fields of papers citing papers by David Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Jones. The network helps show where David Jones may publish in the future.

Co-authorship network of co-authors of David Jones

This figure shows the co-authorship network connecting the top 25 collaborators of David Jones. A scholar is included among the top collaborators of David Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Jones. David Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Younossi, Zobair M., Andreas E. Kremer, Mark G. Swain, et al.. (2024). Assessment of fatigue and its impact in chronic liver disease. Journal of Hepatology. 81(4). 726–742. 11 indexed citations
2.
3.
Invernizzi, Pietro, Marco Carbone, David Jones, et al.. (2023). Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial. Liver International. 43(7). 1507–1522. 37 indexed citations
4.
Kremer, Andreas E., Marlyn J. Mayo, Gideon M. Hirschfield, et al.. (2023). Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 80(1). 27–37. 22 indexed citations
5.
Jones, David, Marco Carbone, Pietro Invernizzi, et al.. (2023). Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology Communications. 7(3). e0057–e0057. 22 indexed citations
6.
Pearce, Mark S., et al.. (2022). Quality of life and home parenteral nutrition: a survey of UK healthcare professionals' knowledge, practice and opinions. Journal of Human Nutrition and Dietetics. 36(3). 687–696. 4 indexed citations
7.
Dyson, Jessica, et al.. (2022). Primary biliary cholangitis presenting with Fanconi syndrome: an important phenotype. BMJ Case Reports. 15(8). e248461–e248461.
8.
Kremer, Andreas E., Marlyn J. Mayo, Gideon M. Hirschfield, et al.. (2021). Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International. 42(1). 112–123. 63 indexed citations
9.
Ibrahim, Ibrahim, Tarek M. Abdelghany, Alex Charlton, et al.. (2021). The methylimidazolium ionic liquid M8OI is detectable in human sera and is subject to biliary excretion in perfused human liver. Toxicology. 459. 152854–152854. 21 indexed citations
10.
Schattenberg, Jörn M., Albert Parés, Kris V. Kowdley, et al.. (2021). A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology. 74(6). 1344–1354. 125 indexed citations
11.
Jones, David, et al.. (2020). A Very Rare Case of Immunoglobulin A Vasculitis in an Adult with Alcoholic Liver Cirrhosis. 2(3). 2 indexed citations
12.
Rice, Stephen, Viviana Albani, Gulnar Fattakhova, et al.. (2020). Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. Clinical Gastroenterology and Hepatology. 19(4). 768–776.e10. 14 indexed citations
13.
Hegade, Vinod S., Alexandros Pechlivanis, Julie A. K. McDonald, et al.. (2019). Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver International. 39(5). 967–975. 32 indexed citations
14.
Abdelghany, Tarek M., Jeremy M. Palmer, Martin P. Cooke, et al.. (2019). The toxicity of the methylimidazolium ionic liquids, with a focus on M8OI and hepatic effects. Food and Chemical Toxicology. 136. 111069–111069. 67 indexed citations
15.
Khanna, Amardeep, Laura Jopson, Denise Howel, et al.. (2018). Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial. SHILAP Revista de lepidopterología. 5(2). 1–78. 6 indexed citations
16.
17.
Jopson, Laura, Julia L. Newton, Jeremy M. Palmer, et al.. (2015). RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMJ Open. 5(8). e007985–e007985. 18 indexed citations
18.
Jones, David, Kieren G. Hollingsworth, Djordje G. Jakovljević, et al.. (2011). Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case–control study. European Journal of Clinical Investigation. 42(2). 186–194. 56 indexed citations
19.
Hollingsworth, Kieren G., David Jones, Roy Taylor, Andrew M. Blamire, & Julia L. Newton. (2010). Impaired cardiovascular response to standing in Chronic Fatigue Syndrome. European Journal of Clinical Investigation. 40(7). 608–615. 51 indexed citations
20.
Prince, Martin I. & David Jones. (2001). Measuring fatigue in medically unwell and distressed patients. Current Opinion in Psychiatry. 14(6). 585–590. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rudolf Stauber Breakdown of academic impact, for papers by Zhiping Li Breakdown of academic impact, for papers by W.H.J. Summerskill Breakdown of academic impact, for papers by Xin Gao Breakdown of academic impact, for papers by R. P. H. Thompson Breakdown of academic impact, for papers by Andrea Fabbri Breakdown of academic impact, for papers by Keh‐Sung Tsai Breakdown of academic impact, for papers by Liang Du Breakdown of academic impact, for papers by Wladimiro Jiménez Breakdown of academic impact, for papers by Srinivasan Dasarathy
Rankless by CCL
2026